DK3704108T3 - Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling - Google Patents

Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling Download PDF

Info

Publication number
DK3704108T3
DK3704108T3 DK18873778.7T DK18873778T DK3704108T3 DK 3704108 T3 DK3704108 T3 DK 3704108T3 DK 18873778 T DK18873778 T DK 18873778T DK 3704108 T3 DK3704108 T3 DK 3704108T3
Authority
DK
Denmark
Prior art keywords
inhibitor
bcl
cancer
treatment
combination
Prior art date
Application number
DK18873778.7T
Other languages
Danish (da)
English (en)
Inventor
Robert Booher
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK3704108T3 publication Critical patent/DK3704108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18873778.7T 2017-10-31 2018-10-30 Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling DK3704108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579502P 2017-10-31 2017-10-31
PCT/US2018/058194 WO2019089580A1 (en) 2017-10-31 2018-10-30 Compounds and compositions for treating hematological disorders

Publications (1)

Publication Number Publication Date
DK3704108T3 true DK3704108T3 (da) 2024-06-10

Family

ID=66328095

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18873778.7T DK3704108T3 (da) 2017-10-31 2018-10-30 Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling

Country Status (26)

Country Link
US (3) US10758518B2 (https=)
EP (2) EP3704108B1 (https=)
JP (3) JP7241747B2 (https=)
KR (2) KR20240130818A (https=)
CN (2) CN111225911B (https=)
AU (3) AU2018359248B2 (https=)
BR (1) BR112020008214A2 (https=)
CA (1) CA3079628A1 (https=)
DK (1) DK3704108T3 (https=)
EA (1) EA202090497A1 (https=)
ES (1) ES2979273T3 (https=)
FI (1) FI3704108T3 (https=)
HR (1) HRP20240700T1 (https=)
HU (1) HUE067356T2 (https=)
IL (3) IL315025A (https=)
LT (1) LT3704108T (https=)
MX (2) MX2020003666A (https=)
MY (1) MY203827A (https=)
PH (1) PH12020550457A1 (https=)
PL (1) PL3704108T3 (https=)
PT (1) PT3704108T (https=)
RS (1) RS65572B1 (https=)
SG (1) SG11202002386WA (https=)
SI (1) SI3704108T1 (https=)
SM (1) SMT202400216T1 (https=)
WO (1) WO2019089580A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
DK3600270T3 (da) 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
CA3079628A1 (en) * 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders
US20220298139A1 (en) * 2019-09-24 2022-09-22 Shanghai Meiyue Biotech Development Co., Ltd. Irak inhibitor and preparation method therefor and use thereof
US20230151025A1 (en) 2020-04-07 2023-05-18 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
CN116419752A (zh) * 2020-08-03 2023-07-11 柯瑞斯公司 用于治疗疾病和病症的组合物和方法
CA3199157A1 (en) * 2020-11-18 2022-05-27 Reinhard Von Roemeling Methods of treating diseases and disorders
JP7620711B2 (ja) * 2020-12-25 2025-01-23 メッドシャイン ディスカバリー インコーポレイテッド アミドオキサゾール系化合物
KR20240004476A (ko) * 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
EP4434981A4 (en) 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
CA3251930A1 (en) * 2022-05-11 2023-11-16 Curis, Inc. TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
AU2024368208A1 (en) * 2023-10-27 2026-04-16 Curis, Inc. Methods of treating cancer associated with reduced interleukin 1 beta expression

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
DK1618092T3 (da) 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
JP2006526660A (ja) 2003-06-05 2006-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｖｒ１レセプターのモジュレーター
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
MXPA06012104A (es) 2004-04-22 2007-01-25 Bayer Cropscience Lp Metodo y composicion para controlar malas hierbas.
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
MX2007007226A (es) 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CN102633783A (zh) 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
KR20090049076A (ko) 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
EP2170834B1 (en) 2007-07-16 2014-01-08 AbbVie Inc. Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
MX2010001446A (es) 2007-08-08 2010-03-01 Merck Serono Sa Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple.
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
CN102281919A (zh) 2008-11-19 2011-12-14 先灵公司 二酰基甘油酰基转移酶的抑制剂
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
US20130053382A1 (en) 2010-04-30 2013-02-28 Sunil Paliwal Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
KR20180099933A (ko) 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
CN106974913A (zh) 2011-04-12 2017-07-25 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6372666B2 (ja) 2012-11-03 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
EP3102569A1 (en) 2014-02-06 2016-12-14 AbbVie Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
JP2018524365A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としての置換アザ化合物
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
JP6994454B2 (ja) * 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED
CA3079628A1 (en) * 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders

Also Published As

Publication number Publication date
MY203827A (en) 2024-07-19
JP2024096919A (ja) 2024-07-17
RS65572B1 (sr) 2024-06-28
MX2023010882A (es) 2023-09-27
CA3079628A1 (en) 2019-05-09
HUE067356T2 (hu) 2024-10-28
PH12020550457A1 (en) 2021-03-22
IL308364A (en) 2024-01-01
KR20240130818A (ko) 2024-08-29
LT3704108T (lt) 2024-06-25
SG11202002386WA (en) 2020-04-29
IL274248B1 (en) 2024-02-01
HRP20240700T1 (hr) 2024-08-16
IL315025A (en) 2024-10-01
JP2023071915A (ja) 2023-05-23
PT3704108T (pt) 2024-06-11
CN111225911B (zh) 2023-09-01
JP7241747B2 (ja) 2023-03-17
AU2023222890A1 (en) 2023-09-14
EP3704108A4 (en) 2021-08-25
WO2019089580A1 (en) 2019-05-09
ES2979273T3 (es) 2024-09-25
CN111225911A (zh) 2020-06-02
JP7476380B2 (ja) 2024-04-30
KR102697663B1 (ko) 2024-08-21
US20200345704A1 (en) 2020-11-05
IL308364B1 (en) 2024-10-01
AU2018359248B2 (en) 2023-06-01
EP4410377A2 (en) 2024-08-07
AU2023222890B2 (en) 2025-04-17
CN117064897A (zh) 2023-11-17
SMT202400216T1 (it) 2024-07-09
EA202090497A1 (ru) 2020-11-23
US10758518B2 (en) 2020-09-01
US20190134010A1 (en) 2019-05-09
AU2018359248A1 (en) 2020-03-26
PL3704108T3 (pl) 2024-07-22
EP4410377A3 (en) 2024-11-13
BR112020008214A2 (pt) 2020-10-27
AU2025205341A1 (en) 2025-07-31
EP3704108B1 (en) 2024-04-24
MX2020003666A (es) 2020-08-03
KR20200080254A (ko) 2020-07-06
IL274248B2 (en) 2024-06-01
EP3704108A1 (en) 2020-09-09
NZ762393A (en) 2025-07-25
IL308364B2 (en) 2025-02-01
SI3704108T1 (sl) 2024-07-31
FI3704108T3 (fi) 2024-05-23
JP2021501145A (ja) 2021-01-14
IL274248A (en) 2020-06-30
US20220370422A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
DK3704108T3 (da) Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
IL282663A (en) Bt1718 for use in treating cancer
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PL3432982T3 (pl) Urządzenie do zimnej plazmy do traktowania skóry
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HUE059990T2 (hu) 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként
IL251904A0 (en) Apilimod for use in the treatment of melanoma
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
PT3773589T (pt) Inibidor de ret para utilização no tratamento de cancro com alteração de ret
HUE054065T2 (hu) Szerek glióma kezelésében történõ alkalmazásra
GB2538923B (en) A therapeutic agent for use in the treatment of infections
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL263804A (en) Wnt inhibitors for use in the treatment of fibrosis
IL273863B1 (en) Hemorrhoid treatment device
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra
LT3405197T (lt) Delgocitinibo panaudojimas lėtinės rankų egzemos gydymui
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism